China Molecular Diagnostics Market to 2024: A Growing Rapidly Market Due to the Rising Incidence of Cancer and Infectious Diseases
DUBLIN, Jan. 14, 2019 /PRNewswire/ --
The "China Molecular Diagnostics Market, Volume, by Application, Infectious Disease Testing, and Genetic Disease Testing" report has been added to ResearchAndMarkets.com's offering.
China Molecular Diagnostics Market is projected to reach US$ 1.8 Billion by the end of year 2024
Molecular diagnostics is a technique which is used for the molecular biological detection of any change in the structure or expression of patient's genetic material. Molecular diagnostics plays an essential role in the detection and identification of various diseases and has gained more public & healthcare specialist attention than ever before. Today, Molecular diagnostics is changing the face of clinical laboratories by offering easy to use automated molecular systems that provide rapid results with less hands-on time.
China Molecular Diagnostics Market is growing rapidly due to the rising incidence of cancer and infectious diseases in the region. In addition; growing wealthy middle class population, who now are willing to pay more in availing better healthcare facilities and aging population who are more vulnerable to communicable diseases and the development in Chinese healthcare infrastructure are some other factors which are expected to drive China Molecular Diagnostics Market to a new record in the forthcoming years.
Profiles of Private Clinical Labs and Diagnostic Services Companies in China
- Zhejiang Di'an Diagnostics Technology Co., Ltd
- ADICON Clinical Laboratories
- Guangzhou Kingmed Diagnostics Center Co. Ltd.
- Kindstar Global (Privately held)
- BGI-Shenzhen (Privately held)
- OriGene Technologies (Privately held)
Key Topics Covered:
1. Executive Summary
2. China Molecular Diagnostic Market & Test Volume
2.1 China Molecular Diagnostic Market
2.2 China Molecular Diagnostic Test Volume
3. Market Share - China Molecular Diagnostic Volume Share Analysis
3.1 Segments
3.2 Disease
3.3 Oncology Test
3.4 Genetic Test
3.5 Infectious Disease Test
4. Volume Share - China Molecular Diagnostics
4.1 Segments
4.2 Disease
4.3 Oncology Test
4.4 Infectious Disease Test
4.5 Genetic Test
5. Disease - China Molecular Diagnostic Test Volume
5.1 Oncology Test Volume
5.1.1 Breast Cancer Test Volume
5.1.2 Colorectal Cancer Test Volume
5.1.3 Prostate Cancer Test Volume
5.2 Infectious Disease Test Volume
5.2.1 Virology Test Volume
5.2.2 HPV Test Volume
5.3 Genetic Test Volume
5.3.1 Blood Screening Test Volume
5.3.2 HLA Test Volume
6. Disease - China Molecular Diagnostic Market
6.1 Oncology Testing Market
6.1.1 Breast Cancer Testing Market
6.1.2 Colorectal Cancer Testing Market
6.1.3 Prostate Cancer Testing Market
6.2 Infectious Disease Testing Market
6.2.1 Virology Testing Market
6.2.2 HPV Testing Market
6.3 Genetic Testing Market
6.3.1 Blood Screening Market
6.3.2 HLA Testing Market
7. China Healthcare Insurance Schemes
7.1 China Healthcare Insurance Schemes
7.1.1 New Rural Cooperative Medical Scheme (NRCMS)
7.1.2 Urban Employed Basic Medical Insurance (UEBMI)
7.1.3 Urban Resident Basic Medical Insurance (URBMI)
7.1.4 Private Health Insurance
8. Growth Drivers
8.1 Increasing Demand from Middle Class for High Quality Healthcare Products
8.2 Rising Incidences of Lifestyle Diseases in China
8.3 Rapid Development in the Diagnosis of Infectious Diseases in China
8.4 Growth in Private Hospitals & Independent Diagnostic Centers
8.4.1 Increasing the Number of Hospital Beds across all Medical Institutions
9. Challenges
9.1 Lack of Government Support, Public Awareness for Molecular Diagnostics test
9.2 Shortage of Skilled Technicians in China
9.3 Reimbursement Rates varies from Province to Province in China
9.3.1 Chinese Government Regulating Laboratory Testing in China
10. Profiles of Private Clinical Labs and Diagnostic Services Companies
10.1 Zhejiang Di'an Diagnostics Technology Co., Ltd.
10.2 ADICON Clinical Laboratories (Privately held)
10.3 Guangzhou Kingmed Diagnostics Center Co. Ltd.
10.4 Kindstar Global (Privately held)
10.5 BGI - Shenzhen
10.6 OriGene Technologies
For more information about this report visit https://www.researchandmarkets.com/research/s3f7gt/china_molecular?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article